Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine Pharmaceutical Investing
Moleculin Enters Agreement with BSP Pharmaceuticals for its Leukemia Drug Candidate Biotech Investing
Daré Bioscience Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform Biotech Investing
Shire announces revised proposal and extension of PUSU deadline to 8 May 2018 Pharmaceutical Investing
Lexaria Enters Definitive License Agreement with California Cannabis Beverage Manufacturer Cannabis Investing News
Beleave Confirms Receipt of Commitments to Fulfill $5,000,000 Private Placement Cannabis Investing News
Naturally Splendid Acquires Organic Hemp Processing Company Absorbent Concepts (ACI) Cannabis Investing News
Alder BioPharmaceuticals Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine Biotech Investing
Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian Cancer Biotech Investing
